Consistent with the above results, present study indicated that crizotinib showed a trend of better efficacy in the first-line treatment than the second- and later-line treatment for patients with locally advanced or metastatic ALK-positive NSCLC; however, statistical significant difference was undetected.
← all excerpts
Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.
1
—
—